MeSH Browser

MeSH Heading: Apolipoprotein C-III
Tree Number(s): D10.532.091.400.875; D12.776.070.400.400.875; D12.776.521.120.400.875
Unique ID: D053305
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D053305
Scope Note: A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).
Entry Term(s): Apo C-III; Apo C-III-2; ApoC-III; Apolipoprotein C-III-0; Apolipoprotein C-III-1; Apolipoprotein CIII; Sialyl Apo C-III; Sialyl Apolipoprotein C-III
Registry Number: 0
Previous Indexing: Apolipoproteins C (1977-2006)
Public MeSH Note: 2007; APOLIPOPROTEIN C-III was indexed under APOLIPOPROTEINS C 1985-2006 & under APOLIPOPROTEINS 1979-1984
History Note: 2007; use APOLIPOPROTEIN C-III (NM) 1979-2006
Date Established: 2007/01/01
Date of Entry: 2006/07/05
Revision Date: 2013/07/09

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analysis (AN)

antagonists & inhibitors (AI)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

deficiency (DF)

drug effects (DE)

economics (EC)

genetics (GE)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

physiology (PH)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

ultrastructure (UL)

urine (UR)

Apolipoprotein C-III MeSH Descriptor Data 2023